Literature DB >> 9076750

Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists.

K A Grant1, G Colombo, J Grant, M A Rogawski.   

Abstract

The dizocilpine-like discriminative stimulus effects of a variety of channel blocking (uncompetitive) N-methyl-D-aspartate (NMDA) receptor antagonists were examined in rats trained to discriminate dizocilpine (0.17 mg/kg, i.p) from saline in a two-lever operant procedure. The dissociative anesthetic-type NMDA antagonists dizocilpine (ED50 0.05 mg/kg), phencyclidine (ED50 3.4 mg/kg) and ketamine (ED50 14 mg/kg) showed complete substitution without producing significant decreases in response rates, whereas dexoxadrol (ED50 4.3 mg/kg) also produced complete substitution with a concomitant decrease (35%) in response rate. Similarly, the low-affinity antagonist memantine resulted in complete substitution (ED50 9.7 mg/kg) at doses that significantly reduced (68%) the response rate. All other low-affinity antagonists resulted in either partial or no substitution for the discriminative stimulus effects of dizocilpine at doses that significantly decreased average response rates. These include (ED50 values in parentheses) remacemide (29 mg/kg), the remacemide metabolite 1,2-diphenyl-2-propylamine (ARL 12495) (14 mg/kg), phencylcyclopentylamine (25 mg/kg), dextromethorphan (46 mg/kg), (+/-)-5-aminocarbonyl-10,11-dihydro -5H-dibenzo-[a,d]cyclohepten-5,10-imine (ADCI; no substitution) and levoxadrol (no substitution). We conclude that low-affinity uncompetitive NMDA antagonists have discriminative stimulus properties distinct from dissociative anesthetic-type uncompetitive NMDA antagonists. The lowest-affinity antagonists show virtually no substitution for dizocilpine, whereas the relatively more potent low-affinity antagonists (such as memantine) exhibit greater substitution, but complete substitution is obtained only at rate-reducing doses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9076750     DOI: 10.1016/s0028-3908(96)00147-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Effects of drugs and drug combinations in pigeons trained to discriminate among pentobarbital, dizocilpine, a combination of these drugs, and saline.

Authors:  D E McMillan; William D Wessinger; Mi Li
Journal:  J Exp Anal Behav       Date:  2009-11       Impact factor: 2.468

2.  Role of altered structure and function of NMDA receptors in development of alcohol dependence.

Authors:  József Nagy; Sándor Kolok; András Boros; Péter Dezso
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 3.  Recent insights into the mode of action of memantine and ketamine.

Authors:  Jon W Johnson; Nathan G Glasgow; Nadezhda V Povysheva
Journal:  Curr Opin Pharmacol       Date:  2014-12-02       Impact factor: 5.547

4.  Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

5.  The discriminative stimulus effects of N-methyl-D-aspartate glycine-site ligands in NMDA antagonist-trained rats.

Authors:  Katherine L Nicholson; Robert L Balster
Journal:  Psychopharmacology (Berl)       Date:  2009-01-28       Impact factor: 4.530

6.  Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats.

Authors:  Katherine L Nicholson; Robert L Balster
Journal:  Psychopharmacology (Berl)       Date:  2003-07-08       Impact factor: 4.530

7.  Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats.

Authors:  Shawn E Kotermanski; Jon W Johnson; Edda Thiels
Journal:  Pharmacol Biochem Behav       Date:  2013-05-08       Impact factor: 3.533

8.  Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.

Authors:  Richard Smith; Erik Pioro; Kathleen Myers; Michael Sirdofsky; Kimberly Goslin; Gregg Meekins; Hong Yu; James Wymer; Merit Cudkowicz; Eric A Macklin; David Schoenfeld; Gary Pattee
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.